Vered et al. carried out a Palbociclib Expanded Access Program (EAP) and collected a total of 334 metastatic ER+/HER2- breast cancer patients to prove the good tolerance and the safety of Palbociclib with Letrozole 23. Here, ERBB2 is linked to breast cancer.